Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD1 | P21728 | 9/20 | 0.73 |
| ▸ | DRD2 | P14416 | 7/20 | 0.73 |
| ▸ | DRD5 | P21918 | 6/20 | 0.73 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.63 |
| ▸ | MEN1 | O00255 | 1/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.63 |
| ▸ | GAA | P10253 | 1/20 | 0.63 |
| ▸ | MAPT | P10636 | 1/20 | 0.63 |
| ▸ | PKM | P14618 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.63 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.63 |
| ▸ | DRD4 | P21917 | 3/20 | 0.51 |
| ▸ | DRD3 | P35462 | 4/20 | 0.48 |
| ▸ | MAOA | P21397 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | THPO | P40225 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | MTOR | P42345 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24869713 | 0.93 | DRD1 (0.69) | DRD1DRD2DRD5KDM4EMEN1 | |
| SCHEMBL30897518 | 0.81 | ALDH1A1 (0.54) | DRD1DRD2DRD5KDM4EMEN1 | |
| SCHEMBL1646406 | 0.78 | ALDH1A1 (0.91) | DRD1DRD2DRD5KDM4EMEN1 | |
| SCHEMBL399808 | 0.78 | MAPT (1.00) | DRD1DRD2DRD5KDM4EMEN1 | |
| SCHEMBL5557727 | 0.77 | KDM4E (0.55) | DRD1DRD2DRD5KDM4EMEN1 | |
| SCHEMBL20939735 | 0.77 | DRD2 (0.47) | DRD1DRD2DRD5DRD4DRD3 | |
| SCHEMBL19236385 | 0.77 | DRD1 (0.53) | DRD1DRD2DRD5KDM4EMAPT | |
| SCHEMBL6247473 | 0.77 | DRD2 (0.62) | DRD1DRD2DRD5DRD4DRD3 | |
| Bromide SCHEMBL10683199 | 0.76 | MAPT (0.95) | DRD1DRD2DRD5KDM4EMEN1 | |
| Bromide SCHEMBL20854693 | 0.75 | DRD2 (0.66) | DRD1DRD2DRD5KDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116888127-A | Tri-fused ring HPK1 inhibitor and application thereof | 轩竹生物科技股份有限公司 | 2023-10-13 | — | — | CN | disclosed |
| US-9676781-B2 | Substituted glycinamides, process for their manufacture and use thereof as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-06-13 | — | — | US | disclosed |
| US-20150252050-A1 | NEW SUBSTITUTED GLYCINAMIDES, PROCESS FOR THEIR MANUFACTURE AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM INT (DE) | 2015-09-10 | — | — | US | disclosed |
| US-9062034-B2 | Substituted glycinamides, process for their manufacture and use thereof as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-06-23 | — | — | US | disclosed |
| US-20130184256-A1 | NEW SUBSTITUTED GLYCINAMIDES, PROCESS FOR THEIR MANUFACTURE AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-07-18 | — | — | US | disclosed |
| EP-1899330-B9 | SUBSTITUTED GLYCINAMIDES HAVING AN ANTITHROMBOTIC AND FACTOR XA-INHIBITING EFFECT | BOEHRINGER INGELHEIM INT (DE) | 2011-11-09 | — | — | EP | disclosed |
| EP-1899330-B1 | SUBSTITUTED GLYCINAMIDES HAVING AN ANTITHROMBOTIC AND FACTOR XA-INHIBITING EFFECT | BOEHRINGER INGELHEIM INT (DE) | 2010-11-24 | — | — | EP | disclosed |
| US-20100216769-A1 | SUBSTITUTED GLYCINAMIDES, PROCESS FOR THEIR MANUFACTURE AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216769-A1 | SUBSTITUTED GLYCINAMIDES, PROCESS FOR THEIR MANUFACTURE AND USE THEREOF AS MEDICAMENTS | PGM2, MGAM, GNMT | DRD1 217/4885DRD2 319/4885DRD5 476/4885 |
| US-20130184256-A1 | NEW SUBSTITUTED GLYCINAMIDES, PROCESS FOR THEIR MANUFACTURE AND USE THEREOF AS MEDICAMENTS | PGM2, MGAM, GRM1 | DRD1 291/4885DRD2 340/4885DRD5 536/4885 |
| US-20150252050-A1 | NEW SUBSTITUTED GLYCINAMIDES, PROCESS FOR THEIR MANUFACTURE AND USE THEREOF AS MEDICAMENTS | PGM2, MGAM, GRM1 | DRD1 291/4885DRD2 340/4885DRD5 536/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.